ReviewJournal of clinical medicine2023
Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- IgA nephropathy with rheumatoid arthritis related to adalimumab.CEN case reports · 2026Article
- Article
- A case of membranous proliferative glomerulonephritis-type IgA nephropathy modified by nintedanib.CEN case reports · 2026Article
- Immune-Mediated IgA Nephropathy Induced by PD-1 Blockade in Extranodal NK/T-Cell Lymphoma.International medical case reports journal · 2026Article
- Acute hepatitis E virus infection as a trigger for postinfectious IgA nephropathy: A rare case report.Medicine · 2025Article
- Concomitant IgA nephropathy and dermatomyositis: a case-based review.Rheumatology international · 2025Review
- IgA Nephropathy in a Patient with Tularemia: Causality or Coincidental Association?Infectious diseases & clinical microbiology · 2025Article
- Immunofluorescence staining profiles of glomerular diseases: a single-center retrospective study.Biochemistry and biophysics reports · 2025Article
- The Immunoglobulin A Nephropathy Renaissance: From Pathogenesis to Personalized Therapy.Cureus · 2025Review
- Rapidly Progressive IgA Nephropathy in a Patient with Systemic Lupus Erythematosus and Chronic Hepatitis B: A Case Report.Reports (MDPI) · 2025Article
- Secondary IgA Vasculitis (sIgAV) Associated with Wilson's Disease.Indian journal of pediatrics · 2025Article
- Acute kidney injury after treatment with arsenic trioxide.Clinical nephrology. Case studies · 2025Article
- The Role of Transforming Growth Factor-β (TGF-β) in Asthma and Chronic Obstructive Pulmonary Disease (COPD).Cells · 2024Review
- Crohn's Disease Associated With IgA Nephropathy Effectively Treated With the Interleukin-23 Inhibitor Risankizumab.ACG case reports journal · 2024Article
- An unsuspected histopathological finding -concomitant IgA nephropathy in a patient with ANCA-associated vasculitis: a case report and literature review.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Primary (pIgAN), secondary IgA nephropathy (sIgAN), and IgA-associated nephropathy can be distinguished. While pIgAN has been thoroughly studied, information about the etiology of sIgAN remains scarce. As concerns sIgAN, several studies suggest that different etiologic factors play a role and ultimately lead to a pathophysiologic process similar to that of pIgAN. In this article, we review a vast number of cases in order to determine the novel putative underlying diseases of sIgAN. Moreover, updates on the common pathophysiology of primary disorders and sIgAN are presented. We identified liver, gastrointestinal, oncological, dermatological, autoimmune, and respiratory diseases, as well as infectious, iatrogenic, and environmental factors, as triggers of sIgAN. As novel biological therapies for listed underlying diseases emerge, we suggest implementing drug-induced sIgAN as a new significant category. Clinicians should acknowledge the possibility of sIgAN progression in patients treated with TNF-α inhibitors, IL-12/IL-23-inhibitors, immune checkpoint inhibitors, CTLA-4, oral anticoagulants, thioureylene derivatives, and anti-vascular endothelial growth factor drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.